Cognition, partners detail study on Early Alzheimer’s

 Cognition Therapeutics Inc., Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer's Disease Research Unit and the Yale Alzheimer's Disease Research Center, is presenting the Phase 2 study design of the company’s ongoing START study in an oral late-breaking session at Clinical Trials on Alzheimer’s Disease (CTAD) conference. The START Study is assessing once-daily oral CT1812 or placebo in 540 individuals with early Alzheimer’s disease for 18 months of treatment. Cognition Therapeutics is conducting the study in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC) with major grant support from the National Institute of Aging (NIA) at the National Institutes of Health.

https://www.biospace.com/article/releases/cognition-therapeutics-and-collaborators-at-yale-and-actc-announce-oral-late-breaking-presentation-on-the-start-study-in-early-alzheimer-s-disease-at-ctad/